deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01709084

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (SALIF)

A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching At Low HIV-1 RNA Into Fixed Dose Combinations (SALIF)

Sponsor: Janssen-Cilag International NV

Conditions Human Immunodeficiency Virus-type 1 Infection
Interventions Efavirenz Emtricitabine Rilpivirine Tenofovir disoproxil fumarate
Updated 14 times since 2017 Last updated: Jan 22, 2021 Started: Oct 2, 2013 Primary completion: Oct 22, 2015 Completion: Jul 2, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01709084, this PHASE3 trial focuses on Human Immunodeficiency Virus-type 1 Infection and remains completed. Sponsored by Janssen-Cilag International NV, it has been updated 14 times since 2013, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Jun 2020 · 12 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Mar 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 9 earlier versions

  1. Feb 2021 — Mar 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2019 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  7. May 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen-Cilag International NV
Data source: Janssen-Cilag International NV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amphur Mueang Nonthaburi, Thailand , Bangkok, Thailand , Bloemfontein, South Africa , Chiang Mai, Thailand , Dakar, Senegal , Douala, Cameroon , Eldoret, Kenya , Entebbe, Uganda , Johannesburg, South Africa , Kampala, Uganda and 8 more locations